Abstract 2384P
Background
In locally advanced/metastatic urothelial carcinoma (UC) which progressed after platinum-based chemotherapy (P), treatment with 2nd-line immune checkpoint inhibitor (ICI) is considered. If disease progresses thereafter, there is no domestically approved drug with proven OS benefit in Korea, despite the development of new drugs. Therefore, P rechallenge is common in clinical practice, in spite of little evidence. This study aimed to evaluate efficacy of P rechallenge, and to explore clinical/genetic biomarkers predicting the efficacy of P rechallenge in locally advanced/metastatic UC.
Methods
A total of 66 patients who rechallenged P for locally advanced/metastatic UC from Jan 2017 to Mar 2023 in 3 tertiary referral hospitals was included. Clinical data were retrospectively evaluated. Next generation sequencing was performed for 43 available patients.
Results
Gemcitabine-based regimens (GP, GCb; [G]; n=28), MVAC-based regimens (MVAC/Cb, ddMVAC; [M]; n=35) and other P (n=3) were administered for P rechallenge; ORR, median PFS and OS were 40.9%, 4.5 and 8.7 months. In patients who received [G] for both 1st-line-P and P-rechallenge (n=24), whose ORR (70.8%) and median TTP (7 months) were favorable to 1st-line P, ORR of P rechallenge was 66.7%. On the other hand, in patients who received 1st-line [G] and rechallenged P with [M] (n=35), whose ORR (45.7%) and mTTP (0.5 months) were relatively poor with 1st-line P, ORR of P rechallenge was 22.9%. Median OS of P rechallenge were significantly longer in patients who received ICI between 1st-line-P and P-rechallenge than those who did not receive (12.4 vs 6.5 months, p=.004). In multivariate analysis, poor response to 1st-line P, visceral metastasis and no alterations in DNA damage repair (DDR) genes were significant prognostic factors for poorer OS after P rechallenge.
Conclusions
This study demonstrated favorable efficacy of P rechallenge in era of ICI in locally advanced/metastatic UC, providing a basis for treatment decision after P and ICI failure. P rechallenge showed fair efficacy even in poorly responded patients from 1st-line P. DDR gene alterations and ICI use before P rechallenge may be associated with improved survival after P rechallenge.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Korean Society of Medical Oncology (KSMO).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2393P - Ephrin signalling mediates resistance to programmed death ligand 1 (PD-L1) inhibition in urothelial carcinoma (UC)
Presenter: Yu-Hsuen Yang
Session: Poster session 24
2394P - Biomarkers of treatment (Tx)-related toxicity in advanced urothelial carcinoma (aUC) pts treated with enfortumab vedotin (EV): Analysis of UNITE study
Presenter: Amanda Nizam
Session: Poster session 24
2395P - Micropapillary histology (MPUC) and extra-cellular domain ERBB2 (ERBB2 ECD+) mutations in urothelial bladder cancer (UBC)
Presenter: Akshay Sood
Session: Poster session 24
2396P - Relationship of tumor fraction in circulating tumor DNA (ctDNA) with prognosis in patients with advanced urothelial cancer
Presenter: Benjamin Miron
Session: Poster session 24
2398P - Are fibroblast growth factor receptor 3 (FGFR3) alterations a possible predictive factor for platinum-based chemotherapy and immunotherapy in metastatic urothelial carcinoma (MUC)?
Presenter: Laura Ferrer-Mileo
Session: Poster session 24
2399P - Circulating tumor DNA and urine tumor DNA detection of minimal residual disease in upper tract urothelial carcinoma with radical nephroureterectomy: A cohort study
Presenter: Wei Xue
Session: Poster session 24
2400P - Frequency and nature of genomic alterations (GA) in ERBB2-altered urothelial bladder cancer (UBC)
Presenter: Rafee Talukder
Session: Poster session 24
2401P - Detection of molecular recurrence in early-stage bladder cancer patients using a urinary tumor DNA assay after transurethral resection of bladder tumor (TURBT)
Presenter: Ruiyun Zhang
Session: Poster session 24